Fulcrum Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Fulcrum Therapeutics, Inc. - FULC
Kahn Swick & Foti, LLC (KSF) is investigating the proposed merger of Fulcrum Therapeutics, Inc. (NasdaqGM: FULC) and Slate Medicines, Inc. The law firm is examining whether the merger and its process are fair to Fulcrum shareholders, who are expected to own 5.0% of the combined company. Shareholders are encouraged to contact KSF for legal consultation regarding their rights.
Slate Medicines to Merge With Fulcrum Therapeutics
Cooley advised Slate Medicines on its definitive agreement to combine with Fulcrum Therapeutics in an all-stock reverse merger. The combined company will operate as Slate Medicines, Inc. and is expected to trade on Nasdaq under "SLTE." In conjunction with the merger, Cooley also advised Slate on an oversubscribed concurrent private placement financing of $245 million.
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact the Firm Regarding an Investigation Into Possible Securities Law Violations
Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) following a significant drop in its stock price. The decline occurred after the company announced the discontinuation of its pociredir program for sickle cell disease due to FDA concerns about malignancy risks associated with PRC2 inhibitors. Investors who suffered losses are encouraged to contact Kaplan Fox for more information regarding this investigation.
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact the Firm Regarding an Investigation Into Possible Securities Law Violations
Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations by Fulcrum Therapeutics, Inc. (NASDAQ: FULC) after the company discontinued its pociredir program due to FDA concerns about an unexpectedly high rate of secondary hematologic malignancies. This announcement led to a significant 51.09% drop in Fulcrum Therapeutics' stock price. The firm is encouraging investors who have suffered losses or have relevant information to contact them regarding this investigation.
Shareholder Alert: Ademi LLP investigates whether Fulcrum Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders
Ademi LLP is investigating Fulcrum Therapeutics (Nasdaq: FULC) regarding potential breaches of fiduciary duty related to its transaction with Slate Medicines. The investigation focuses on whether Fulcrum's public shareholders are receiving a fair price, given that they are expected to own only 5.0% of the combined company while Slate shareholders will own 95.0%. The firm is also scrutinizing the board's conduct and the transaction's terms, including a significant penalty for accepting competing bids.
Latham Advises Frazier Life Sciences on Private Placement Financing With Fulcrum Slate Merger
Latham & Watkins LLP advised Frazier Life Sciences on an oversubscribed US$245 million private placement financing. This financing supports the merger between Fulcrum Therapeutics, Inc. (Nasdaq: FULC) and Slate Medicines, Inc., an all-stock transaction. The combined company will focus on advancing Slate’s pipeline, including SLTE-1009 for migraine treatment, and will trade on Nasdaq under the symbol SLTE.
Form 8K Fulcrum Therapeutics Inc For: 17 August By Investing.com
This article reports that Fulcrum Therapeutics Inc. filed a Form 8K on August 17. The filing is brief and does not provide further details within the article text. The content also includes market data and related news headlines.
Fulcrum Therapeutics (NASDAQ: FULC) backs $245M migraine venture with Slate
Fulcrum Therapeutics and Slate Medicines announced an all-stock merger, forming a new entity named Slate Medicines, Inc. that will trade on Nasdaq as "SLTE." The combined company will focus on Slate's pipeline, particularly SLTE-1009 for migraine prevention, supported by a $245 million private placement from investors led by Frazier Life Sciences. This funding is expected to support operations into 2029 as SLTE-1009 advances through clinical trials.
Shareholder Alert: Ademi LLP investigates whether Fulcrum Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders
Ademi LLP is investigating Fulcrum Therapeutics, Inc. (Nasdaq: FULC) regarding its recently announced transaction with Slate Medicines, suspecting possible breaches of fiduciary duty. Under the merger agreement, pre-Merger Fulcrum stockholders are expected to own only 5.0% of the combined company, with Slate stockholders owning 95.0%. The investigation focuses on whether Fulcrum's board is fulfilling its fiduciary duties to shareholders given the low ownership percentage for existing shareholders and a significant penalty if Fulcrum accepts a competing bid.
Fulcrum Therapeutics shuts down, reverse-merges with N.C. biotech Slate
Fulcrum Therapeutics, which previously cut 85% of its workforce after discontinuing its sickle cell disease program, is undergoing a reverse merger with North Carolina-based Slate Medicines. The merger is anticipated to finalize in the fourth quarter of the year. Fulcrum is currently located at 26 Landsdowne St., occupying significant office and laboratory space.
Kaplan Fox Alerts Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Possible Securities Law Violations
Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) after the company announced the discontinuation of its pociredir program for sickle cell disease. This decision followed heightened FDA concerns regarding the drug's benefit-risk profile due to malignancy risks associated with PRC2 inhibitors, leading to a significant 51.09% stock price decline on June 2, 2026. Investors who suffered losses are encouraged to contact Kaplan Fox for more information on the investigation.
Fulcrum Therapeutics stock rises on Slate Medicines merger deal
Fulcrum Therapeutics Inc (NASDAQ:FULC) shares rose after announcing a definitive agreement to merge with Slate Medicines Inc in an all-stock transaction. The combined company, to be named Slate Medicines, will focus on advancing migraine therapeutics and secured an oversubscribed private placement of $245 million to fund operations into 2029. The merger is expected to close in Q4 2026, with Fulcrum stockholders owning 5.0% of the combined entity.
Fulcrum Therapeutics Merges With Slate in $245M Migraine Biotech Deal
Fulcrum Therapeutics is merging with Slate Medicines, a privately held migraine-focused biotech company, in an all-stock transaction valued at $245 million, expected to close in Q4 2026. The combined entity will be renamed Slate Medicines and trade under the Nasdaq ticker SLTE. This deal includes a private placement, a special cash dividend for pre-merger Fulcrum shareholders, and is projected to provide the new company with operational funding until 2029, focusing on Slate's lead migraine drug candidates, SLTE-1009 and SLTE-2100.
Fulcrum to merge with Slate in all-stock deal after drug setback
Fulcrum Therapeutics announced an all-stock merger with privately held Slate Medicines following the discontinuation of its lead drug candidate. The combined company will operate as Slate Medicines, trading under the ticker "SLTE" on Nasdaq, and gains access to Slate's experimental migraine drug, SLTE-1009. The deal includes a $245 million private placement, expected to fund operations into 2029 and advance its pipeline.
Fulcrum (NASDAQ: FULC) plans special cash payout in Slate merger
Fulcrum Therapeutics (NASDAQ: FULC) and Slate Medicines have announced an all-stock merger to create a combined company focused on migraine therapeutics, to be renamed Slate Medicines, Inc. and trade under the symbol SLTE. The merger includes a $245 million private placement for Slate, and Fulcrum stockholders are expected to receive a special cash dividend from approximately $270 million of additional cash at closing, contributing $20.3 million net cash for a 5% ownership stake in the new entity. The combined company's pipeline includes lead candidate SLTE-1009 for migraine prevention, with clinical trials anticipated through 2027, and is expected to have cash runway into 2029.
Fulcrum Therapeutics to Merge With Slate Medicines in Stock Deal Backed by $245 Million Financing
Fulcrum Therapeutics has announced a stock-for-stock merger with Slate Medicines, supported by a $245 million private placement. Upon closing, current Slate holders will own a majority stake, while Fulcrum plans a significant cash dividend to its stockholders, a reverse stock split, and a name change to Slate Medicines. The deal, which includes various support and lock-up agreements, is subject to customary approvals and conditions.
Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies
Fulcrum Therapeutics and Slate Medicines have announced a definitive merger agreement to combine in an all-stock transaction. The combined entity, to be named Slate Medicines, Inc., will focus on advancing Slate's pipeline of next-generation migraine therapeutics, including SLTE-1009, a clinical-stage subcutaneous anti-PACAP/VIP monoclonal antibody. The merger is supported by a concurrent oversubscribed private placement of $245 million, expected to fund operations into 2029 and advance their lead product through Phase 1 and Phase 2 studies.
Therapeutics, Inc. (FULC) RA Capital group now reports 0.0% stake
RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. have filed an amended Schedule 13G/A for Fulcrum Therapeutics, Inc. (FULC). As of June 30, 2026, the group collectively beneficially owned 0 shares, representing 0.0% of the common stock. This filing indicates they no longer hold significant voting or dispositive power over the company's shares.
Fulcrum Therapeutics (FULC) investor group reduces reported ownership to 0%
An investor group comprising TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC, and Chen Yu has filed an amended Schedule 13G/A, reporting that their beneficial ownership of Fulcrum Therapeutics (FULC) common stock has been reduced to 0%. The filing indicates they no longer hold any shares and affirm ownership of 5% or less of the outstanding class. This change reflects no sole or shared voting or dispositive power over Fulcrum shares by the reporting persons.
Kaplan Fox Investigates Fulcrum Therapeutics After 51% Stock Plunge Following Pociredir Program Halt
Kaplan Fox & Kilsheimer LLP has initiated an investigation into Fulcrum Therapeutics (NASDAQ: FULC) following a 51% stock drop. The plunge occurred after Fulcrum unexpectedly halted its pociredir program for sickle cell disease due to FDA concerns over its benefit-risk balance. The investigation will examine whether Fulcrum adequately informed investors about the drug's regulatory and safety risks.
Assenagon Asset Management S.A. Has $3.06 Million Position in Fulcrum Therapeutics, Inc. $FULC
Assenagon Asset Management S.A. reduced its stake in Fulcrum Therapeutics (NASDAQ:FULC) by 30% in the second quarter, selling 358,669 shares and retaining 835,204 shares valued at $3.06 million. The company's shares opened at $3.71, near its 12-month low, and it reported a quarterly loss of $0.34 per share, missing analyst expectations. Several analysts have downgraded the stock to "hold" or "neutral" ratings, with a consensus "Reduce" rating and an average price target of $8.20.
Fulcrum Therapeutics, Inc. Appoints Alan Musso as Principal Accounting Officer, Effective August 7, 2026
Fulcrum Therapeutics, Inc. announced the appointment of Alan Musso as Principal Accounting Officer, effective August 7, 2026. Musso, who currently serves as Fulcrum's chief financial officer and principal financial officer, takes on this additional role following Mr. Tourangeau's departure. The change was communicated on August 9, 2026.
Fulcrum Therapeutics stock plunges 51% after FD...
Fulcrum Therapeutics' stock plummeted 51% after the FDA halted development of its sickle cell disease drug, pociredir, due to serious safety concerns. The FDA's decision, prompted by malignancy risks linked to similar drugs, effectively ends clinical development for pociredir, significantly impacting Fulcrum's future. This severe drop in stock price has led to a securities investigation by Kaplan Fox & Kilsheimer LLP.
Form 8K Fulcrum Therapeutics Inc For: 10 August By Investing.com
This article announces that Fulcrum Therapeutics Inc. filed a Form 8K on August 10th. The filing is a standard corporate disclosure that typically reports significant events relevant to shareholders. The brief piece is published by Investing.com, a financial markets news outlet.
Fulcrum Therapeutics appoints Alan Musso as principal accounting officer
Fulcrum Therapeutics announced that Alan Musso, its current chief financial officer, has been appointed to the additional role of principal accounting officer, effective August 7, 2026. This appointment follows the departure of Greg Tourangeau from the Vice President, Finance and principal accounting officer position. Musso will not receive additional compensation for this expanded role, and the company confirmed no conflicts of interest.
BofA Securities Maintains Fulcrum Therapeutics(FULC.US) With Sell Rating, Maintains Target Price $3
BofA Securities has maintained its Sell rating on Fulcrum Therapeutics (FULC.US) and kept its target price at $3. This indicates a continued bearish outlook from the firm regarding the company's stock performance.
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (FULC) Who Suffered Losses to Contact the Firm Regarding a Securities Investigation
Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) after the company discontinued its pociredir program for sickle cell disease. The discontinuation followed heightened FDA concerns about the drug's benefit-risk profile due to malignancy risks associated with its class of drugs. This news led to a significant 51.09% drop in Fulcrum Therapeutics' stock price, prompting the firm to encourage affected investors to contact them.
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Recommendation of "Reduce" from Analysts
Fulcrum Therapeutics (NASDAQ:FULC) has received a consensus "Reduce" recommendation from analysts, with an average 12-month price target of $8.20. Several firms recently downgraded the stock and set lower price targets. This comes as the company missed quarterly earnings expectations and its shares remain significantly below their 52-week high.
Fulcrum Therapeutics (FULC) Stock Sees Modest Fair Value Lift After Pociredir Exit
Fulcrum Therapeutics (FULC) has seen a modest increase in its Fair Value estimate from US$5.43 to US$5.83 per share, according to Simply Wall St. This adjustment follows the company's decision to discontinue its drug pociredir, leading to a shift in analyst focus towards cash preservation, restructuring, and exploring new options. Analysts have provided mixed sentiments, with some highlighting the company's cash-rich balance sheet and others expressing caution due to the lack of a clear pipeline and FDA concerns regarding the PRC2 inhibitor class.
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact the Firm Regarding Potential Securities Law Violations
Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations by Fulcrum Therapeutics, Inc. (NASDAQ: FULC) after the company announced the discontinuation of its pociredir program due to FDA concerns about malignancy risk. This news led to a significant 51.09% drop in Fulcrum Therapeutics' stock price on June 2, 2026. The firm is encouraging investors who suffered losses to contact them for more information regarding the investigation.
Bank of America (NYSE: BAC) reports 6.7% holding in Fulcrum Therapeutics (FULC)
Bank of America Corporation, through its wholly-owned subsidiaries, has reported a beneficial ownership of 6.7% in Fulcrum Therapeutics, Inc. This stake, amounting to 4,468,123 shares of common stock, is based on Fulcrum Therapeutics' reported 66,633,321 shares outstanding as of April 20, 2026. The filing indicates that Bank of America and its subsidiaries hold shared voting and shared dispositive power over these shares, with no sole voting or dispositive power.
Fulcrum Therapeutics, Inc. 2Q 2026: Net loss $(26.2M), EPS $(0.34) — 10-Q Summary
Fulcrum Therapeutics, Inc. reported a significant net loss of $(26.2M) and diluted EPS of $(0.34) for 2Q 2026, widening from the previous year, with no revenue generated. The company discontinued its sickle cell disease program, reduced its workforce by 85%, and initiated a strategic review including potential M&A or asset sales. Fulcrum has ceased R&D activities and anticipates near-term charges related to restructuring and advisory fees as it winds down operations.
Truist Financial Downgrades Fulcrum Therapeutics(FULC.US) to Hold Rating, Cuts Target Price to $4
Truist Financial has downgraded Fulcrum Therapeutics (FULC.US) to a Hold rating from a Buy rating, citing increased risk in their FA/FSHD programs. The firm has also significantly cut its price target for FULC.US from $15 to $4. This adjustment reflects a more cautious outlook on the company's prospects.
Fulcrum Therapeutics Market Sentiment
This article analyzes the market sentiment for Fulcrum Therapeutics (FULC) based on several key signals: analyst consensus, short interest, options flow, and insider activity. The overall analyst consensus is "Hold" with a target price of $8.00, while short interest is rising, and insider activity shows net buying. The article also provides a detailed list of recent analyst actions including upgrades, downgrades, and initiations with their respective price targets and rating changes.
Fulcrum Therapeutics Inc (FULC) Financial Health: Profitability & Balance Sheet Analysis
This article analyzes the financial health of Fulcrum Therapeutics Inc (FULC), noting its current financial score of 7.26, which ranks 138 out of 385 in the Biotechnology & Medical Research industry, indicating a weak financial status but high operating efficiency. The report highlights that key data for profitability, balance sheet, and operational efficiency metrics have not yet been disclosed by the company. It also shows a slight drop in the stock price as of the closing on July 28th.
FULC|Fulcrum Therapeutics Inc|Price:3.725|Chg%:-0.005
This article provides a comprehensive stock analysis of Fulcrum Therapeutics Inc (FULC) from TradingKey. It highlights that FULC has relatively weak fundamentals but high growth potential, is fairly valued, and has very high institutional ownership. Analysts generally rate it as a "Hold" with a target price indicating significant upside, though the stock is expected to trend down in the medium term.
BlackRock discloses 7.2% ownership of Therapeutics Inc (FULC) in updated filing
BlackRock, Inc. has filed an Amendment No. 4 to Schedule 13G/A, announcing its beneficial ownership of 7.2% of the common stock of Fulcrum Therapeutics Inc (FULC). This amounts to 4,802,880 shares, with BlackRock holding sole voting power over 4,736,507 shares and sole dispositive power over all 4,802,880 shares. The filing indicates that this investment is held in the ordinary course of business and not for the purpose of influencing control of the issuer.
Kaplan Fox & Kilsheimer LLP Announces an Investigation into Fulcrum Therapeutics, Inc. (FULC) for Possible Securities Law Violations
Kaplan Fox & Kilsheimer LLP has announced an investigation into Fulcrum Therapeutics, Inc. (FULC) for potential securities law violations after the company discontinued its pociredir program for sickle cell disease. This decision followed feedback from the FDA indicating concerns about the benefit-risk profile of the drug, leading to a significant 51.09% drop in Fulcrum Therapeutics' stock price on June 2, 2026. The law firm is seeking investors who suffered losses to assist in the investigation.
Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for Potential Securities Law Violations - Investors Encouraged to Contact the Firm
Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations by Fulcrum Therapeutics, Inc. (NASDAQ: FULC). This investigation follows the company's announcement on June 1, 2026, to discontinue its pociredir program for sickle cell disease due to heightened FDA concerns regarding the drug's benefit-risk profile and its association with secondary hematologic malignancies, similar to another withdrawn PRC2 inhibitor. Following this news, Fulcrum Therapeutics' stock price dropped significantly by over 51%.
Fulcrum Therapeutics Inc (FULC) Institutional Confidence
Fulcrum Therapeutics Inc (FULC) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. Institutional shareholding proportion stands at 104.53%, a decrease of 26.94% quarter-over-quarter. Steven Cohen is the largest institutional shareholder, holding 2.35M shares, which represents 3.12% of shares outstanding.
Kaplan Fox Launches Securities Probe Into Fulcrum Therapeutics After Pociredir Program Halt Sparks Stock Plunge
Kaplan Fox & Kilsheimer LLP has initiated a securities investigation into Fulcrum Therapeutics, Inc. (NASDAQ: FULC) following the company's decision on June 1, 2026, to discontinue its pociredir program for sickle cell disease. This announcement led to a significant drop in Fulcrum Therapeutics' stock price. The law firm is currently seeking investors who incurred losses and anyone possessing relevant information to aid in their investigation.
Fulcrum Therapeutics Inc (FULC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey provides a revenue breakdown for Fulcrum Therapeutics Inc (FULC). It notes that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The page also includes current stock information for FULC.
ETFs Investing in Fulcrum Therapeutics, Inc. Stocks
This article lists several ETFs that hold stocks of Fulcrum Therapeutics, Inc. (FULC), a pharmaceuticals company. The list provides details such as market value, weight of FULC in the ETF, issuer, management style, expense ratio, and recent performance for each fund. These ETFs offer investors diversified access to FULC stock with potentially lower risk.
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (FULC) Who Suffered Losses to Contact the Firm Regarding a Securities Investigation
Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. (FULC) after the company discontinued its pociredir program due to FDA concerns regarding its benefit-risk profile and an associated high rate of secondary hematologic malignancies. This announcement led to a significant 51.09% drop in Fulcrum Therapeutics' stock price. The firm is encouraging investors who suffered losses to contact them for more information regarding the investigation.
Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for Potential Securities Law Violations - Investors are Encouraged to Contact the Firm
Kaplan Fox & Kilsheimer LLP is investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for potential securities law violations after the company announced the discontinuation of its pociredir program for sickle cell disease. This decision followed FDA concerns regarding the drug's benefit-risk profile due to an unexpectedly high rate of secondary hematologic malignancies associated with another PRC2 inhibitor. Following this news, Fulcrum Therapeutics' stock price dropped over 51%.
Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for Potential Securities Law Violations - Investors are Encouraged to Contact the Firm
Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations by Fulcrum Therapeutics, Inc. (NASDAQ: FULC) following a significant drop in its stock price. The investigation stems from the company's June 1, 2026 announcement to discontinue its pociredir program for sickle cell disease due to FDA concerns about malignancy risk associated with PRC2 inhibitors. Investors who suffered losses are encouraged to contact Kaplan Fox for more information.
Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for Potential Securities Law Violations - Investors are Encouraged to Contact the Firm
Kaplan Fox & Kilsheimer LLP is investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for potential securities law violations. This investigation follows Fulcrum's announcement on June 1, 2026, of the discontinuation of its pociredir program for sickle cell disease due to FDA concerns regarding the drug's benefit-risk profile. The company's stock subsequently dropped over 51%.
Kaplan Fox Announces an Investigation Into Fulcrum Therapeutics
Kaplan Fox & Kilsheimer LLP has initiated an investigation into Fulcrum Therapeutics, Inc. (NASDAQ: FULC) regarding potential securities law violations. This follows a significant drop in Fulcrum's stock price after the company announced the discontinuation of its pociredir program for sickle cell disease due to FDA concerns over malignancy risk associated with its drug class. Investors who experienced losses are encouraged to contact Kaplan Fox.
Fulcrum Therapeutics 10% owner Kevin Tang acquires $594,132 of common shares
Kevin Tang, a 10% owner of Fulcrum Therapeutics through Tang Capital, has acquired an additional $594,132 worth of the company's common stock. The purchases were made at prices between $3.52 and $3.56 per share. Following these transactions, Tang Capital-managed entities now beneficially own 7,080,945 shares of Fulcrum Therapeutics.
Form 4 Fulcrum Therapeutics Inc For: 21 July By Investing.com
This article reports on a Form 4 filing for Fulcrum Therapeutics Inc. dated July 21st, 2026. Form 4 filings typically disclose transactions by company insiders, however, the content beyond the headline is minimal, indicating this islikely an automated news brief. The article notes a 1.66% increase in FULC's stock at the time of publication.
